Pharmaceuticals

Landmark Phase 3 data for HBI-8000 not only offers new hope for melanoma patients but validates a powerful "China-to-global" drug development strategy.

With a fresh $150M, Mighty Therapeutics is set to expand its groundbreaking mitochondrial drugs from rare diseases to major conditions like Parkinson's.

Atrium Therapeutics' clinical trial for a rare cardiomyopathy isn't just a milestone; it's a strategic maneuver signaling the arrival of precision RNA therapies in cardiology.

Elevara Medicines taps biotech veteran Dr. Mai-Britt Zocca to lead its charge against rheumatoid arthritis with a novel drug and $70M in backing.

A new watchdog emerges as millions use unapproved GLP-1 drugs, many believing they're FDA-approved. How a shortage solution became a risky shadow market.

Eupraxia Pharmaceuticals is overhauling its leadership and relocating to major biotech hubs, betting it all on its late-stage pipeline and a pivotal trial.

Milla Pharmaceuticals' new FDA approval for a vital acidosis drug offers hope for hospitals battling chronic shortages and marks a key strategic win for parent A.forall.

How one company's relentless focus on data-driven quality, validated by a prestigious URAC 'Pioneer' award, is redefining safety standards in specialized medicine.

With a new CMO, $50M in fresh capital, and pivotal trials on the horizon, Cue Biopharma makes a strategic bet on an immunology veteran to guide its future.

After an initial rejection, Sydnexis's pediatric myopia drug gets a crucial FDA hearing, raising hopes for the first approved U.S. pharmaceutical treatment.

Alto Neuroscience's $100M raise fuels its quest to treat resistant depression. It's a high-stakes play on a biomarker-driven approach in a challenging field.

Delonix Bioworks is running parallel trials in China and Australia for its MenB vaccine, a strategic gambit that could disrupt a billion-dollar market.

A novel drug, LM11A-31, paired with advanced brain mapping, shows promise by preserving neural networks, marking a potential shift from targeting plaques.

Backed by $180M, Celea Therapeutics is deploying a bold head-to-head superiority trial, aiming to prove its drug isn't just an alternative but a new standard.

This Monday, Q32 Bio will unveil pivotal data for its alopecia areata drug. For 700,000 Americans, it could mean a new path beyond today's treatments.

MindRank's AI platform propelled a GLP-1 drug to Phase III in record time. Its new $52M funding aims to prove this isn't a one-off, but a revolution.

The biotech's complex warrant restructuring is more than a balance sheet clean-up; it's a strategic masterstroke paving the way for its MASH drug.

Rani Therapeutics partners with PegBio, betting its drug-injecting capsule can unlock novel oral obesity therapies and challenge market giants.

Serina Therapeutics' Parkinson's drug SER-252 advances, but the real story is its POZ Platform, a technology that could reshape drug delivery.

As the 340B drug pricing program grows more complex, safety-net providers are losing vital funds. A new approach urges independent oversight to stop the leakage.